AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7984241 — intervention group
Group type: EXPERIMENTAL
Intervention: Topoisomerase II activity
Number of subjects: 0
Study 7984241 — intervention group
Group type: EXPERIMENTAL
Intervention: Catenation-sensitive checkpoint mechanism
Number of subjects: 0
Study 32777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofisopam
Number of subjects: 57
Study 32777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 30910899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (CAZ-AVI)
Number of subjects: 284
Study 30910899 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy (BAT)
Number of subjects: 284
Study 29909113 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography (CTA)
Number of subjects: 400
Study 29909113 — intervention group
Group type: COMPARATOR
Intervention: Stress Echocardiography (SE)
Number of subjects: 400
Study 26950350 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy Squat (HS) with 80% of maximum load
Number of subjects: 10
Study 26950350 — intervention group
Group type: COMPARATOR
Intervention: Unloaded Jump Squat (JS)
Number of subjects: 10
Study 25193431 — intervention group
Group type: EXPERIMENTAL
Intervention: FMI (final market image)
Number of subjects: 23
Study 25193431 — intervention group
Group type: COMPARATOR
Intervention: HF meal (high fat)
Number of subjects: 23
Study 25193431 — intervention group
Group type: COMPARATOR
Intervention: LF meal (low fat)
Number of subjects: 23
Study 22880108 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 150
Study 22880108 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 150
Study 22880108 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aerobic and resistance exercise
Number of subjects: 150
Study 22880108 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 22880108 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study 19249998 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program (12-week, twice-weekly sessions including asanas and visama vritti pranayama)
Number of subjects: 29
Study 19249998 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 29
Study 19249998 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 29
Study 17898245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 1,000 microg/day with Salmeterol 100 microg/day
Number of subjects: 137
Study 17898245 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone 1,000 microg/day alone
Number of subjects: 137
Study 15078254 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (37, 16, and 10 l annually)
Number of subjects: 583
Study 15078254 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 non‐donors)
Number of subjects: 583
Study 11966951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy for 2 years
Number of subjects: 90
Study 11966951 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 2 years
Number of subjects: 90
Study 10325999 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% topical aqueous phenylephrine
Number of subjects: 54
Study 10325999 — intervention group
Group type: COMPARATOR
Intervention: 10% topical aqueous phenylephrine
Number of subjects: 54
Study 7584198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo/Cuff (CC)
Number of subjects: 44
Study 7584198 — intervention group
Group type: COMPARATOR
Intervention: Ice therapy (ICE)
Number of subjects: 44
Study 2626528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 8
Study 2626528 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific psychotherapy
Number of subjects: 8
Study 776322 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage group
Number of subjects: 143
Study 776322 — intervention group
Group type: COMPARATOR
Intervention: Non-drainage group
Number of subjects: 143
Study 776322 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective drainage group
Number of subjects: 143
Study 31509196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit ZipTM activity tracker with reporting via text messages, automated telephone calls, and syncing (two weeks each) for six weeks.
Number of subjects: 51
Study 31509196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activity tracker).
Number of subjects: 51
Study 31096036 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg
Number of subjects: 3821
Study 31096036 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 μg
Number of subjects: 3821
Study 31096036 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 250/50 μg
Number of subjects: 3821
Study 28838473 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free biolimus A9 drug-coated stents (DCS)
Number of subjects: 879
Study 28838473 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 879
Study 26036646 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks parent-group intervention to manage restricted and repetitive behaviours (RRB)
Number of subjects: 45
Study 23921776 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Lifestyle Counseling
Number of subjects: 390
Study 23921776 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Brief LC
Number of subjects: 390
Study 23921776 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 390
Study 23921776 — intervention group
Group type: EXPERIMENTAL
Intervention: Food records completed during the first 6 months
Number of subjects: 390
Study 23921776 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving a 5% weight loss at month 6
Number of subjects: 390
Study 21464378 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-focused HIV prevention intervention
Number of subjects: 336
Study 21464378 — intervention group
Group type: COMPARATOR
Intervention: Control condition (basic HIV-AIDS information)
Number of subjects: 336
Study 19458018 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 kcal/d snack food for 2 weeks
Number of subjects: 58
Study 19458018 — intervention group
Group type: COMPARATOR
Intervention: 0 kcal/d snack food for 2 weeks
Number of subjects: 58
Study 19458018 — intervention group
Group type: COMPARATOR
Intervention: 100 kcal/d snack food for 2 weeks
Number of subjects: 58
Study 16885221 — intervention group
Group type: EXPERIMENTAL
Intervention: EBA activation during embodied self location tasks
Number of subjects: 0
Study 16885221 — intervention group
Group type: EXPERIMENTAL
Intervention: TPJ activation during disembodied self location tasks
Number of subjects: 0
Study 14738771 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked priming paradigm with prime durations of 33 and 50 ms for upright faces
Number of subjects: 0
Study 14738771 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked priming paradigm with inverted faces
Number of subjects: 0
Study 14738771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of upright and inverted face processing
Number of subjects: 0
Study 14738771 — intervention group
Group type: EXPERIMENTAL
Intervention: Misaligned faces as primes
Number of subjects: 0
Study 11092071 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced services program providing transportation, outreach, and child-care services
Number of subjects: 0
Study 11092071 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of access services
Number of subjects: 0
Study 11092071 — intervention group
Group type: COMPARATOR
Intervention: Regular substance abuse treatment programs
Number of subjects: 0
Study 9497918 — intervention group
Group type: EXPERIMENTAL
Intervention: One step reverse transcriptase polymerase chain reaction (RT‐PCR) protocol for BCR‐ABL chimaera detection
Number of subjects: 50
Study 9497918 — intervention group
Group type: COMPARATOR
Intervention: Published RT‐PCR procedures
Number of subjects: 50
Study 8097170 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (200 micrograms)
Number of subjects: 9
Study 8097170 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study 3102303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nasogastric tube-feeding
Number of subjects: 0
Study 3102303 — intervention group
Group type: COMPARATOR
Intervention: Best oral feeding
Number of subjects: 0
Study 29653635 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg daily aspirin
Number of subjects: 15480
Study 29653635 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g omega-3 FA daily
Number of subjects: 15480
Study 29653635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15480
Study 28281457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg/day
Number of subjects: 41
Study 28281457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 25061233 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried blood spot testing (DBST) for HCV testing with training and logistic support
Number of subjects: 6
Study 23717490 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-936558 (0.1 mg/kg or 10 mg/kg)
Number of subjects: 54
Study 23717490 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-936558 (10 mg/kg)
Number of subjects: 54
Study 23717490 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-936558
Number of subjects: 54
Study 23717490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 21389841 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic high-intensity hybrid exercise training (3 times a week for 8 weeks)
Number of subjects: 6
Study 21389841 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic high-intensity hybrid exercise training
Number of subjects: 6
Study 18641581 — intervention group
Group type: EXPERIMENTAL
Intervention: WFG‐LASIK
Number of subjects: 61
Study 18641581 — intervention group
Group type: EXPERIMENTAL
Intervention: WFG‐PRK
Number of subjects: 61
Study 18641581 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 18641581 — intervention group
Group type: EXPERIMENTAL
Intervention: WFG‐LASIK and WFG‐PRK
Number of subjects: 61
Study 16557409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-visit system used for 6 weeks after discharge
Number of subjects: 0
Study 16557409 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 14636798 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM
Number of subjects: 188
Study 14636798 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet
Number of subjects: 188
Study 14636798 — intervention group
Group type: COMPARATOR
Intervention: Pamphlets
Number of subjects: 188
Study 10817440 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparosonic coagulating shears (LCS)
Number of subjects: 40
Study 10817440 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 40
Study 8661976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal synthetic SCT (200 IU daily)
Number of subjects: 117
Study 8661976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 8661976 — intervention group
Group type: COMPARATOR
Intervention: Thrice-weekly calcitonin
Number of subjects: 117
Study 8661976 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femur (all groups)
Number of subjects: 117
Study 8661976 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers (all groups)
Number of subjects: 117
Study 1804669 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (100 mg.day-1, intermittent schedule)
Number of subjects: 27
Study 1804669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 1804669 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 27
Study 6289963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 125 mg
Number of subjects: 188
Study 6289963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 62.5 mg
Number of subjects: 188
Study 6289963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 32.5 mg
Number of subjects: 188
Study 6289963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (all doses)
Number of subjects: 188
Study 6289963 — intervention group
Group type: COMPARATOR
Intervention: Kanamycin 2 g
Number of subjects: 188
Study 31824142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 17
Study 31824142 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch exercise
Number of subjects: 17
Study 31824142 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in serum BDNF
Number of subjects: 17
Study 29037658 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial device training
Number of subjects: 40
Study 29037658 — intervention group
Group type: COMPARATOR
Intervention: Standard device training
Number of subjects: 40
Study 29037658 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial device training combined with elastic band exercise
Number of subjects: 40
Study 29037658 — intervention group
Group type: COMPARATOR
Intervention: Standard device training combined with elastic band exercise
Number of subjects: 40
Study 29037658 — intervention group
Group type: COMPARATOR
Intervention: Artificial device (with or without EB exercise)
Number of subjects: 40
Study 25855073 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative drug therapy to prevent disease recurrence
Number of subjects: 174
Study 23980084 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib 800 mg once daily orally
Number of subjects: 1155
Study 23980084 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice daily orally
Number of subjects: 1155
Study 21725579 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilate (high purity, human plasma-derived VWF/FVIII concentrate)
Number of subjects: 22
Study 21725579 — intervention group
Group type: COMPARATOR
Intervention: Humate-P (intermediate purity, human plasma-derived VWF/FVIII concentrate)
Number of subjects: 22
Study 21725579 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilate
Number of subjects: 22
Study 21725579 — intervention group
Group type: COMPARATOR
Intervention: Humate-P
Number of subjects: 22
Study 19850525 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (0.9 mg/kg bodyweight)
Number of subjects: 821
Study 16362400 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min brisk semi-self-paced walk
Number of subjects: 60
Study 16362400 — intervention group
Group type: COMPARATOR
Intervention: Passive control condition
Number of subjects: 60
Study 15296367 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (3 MHz, 0.5 W/cm2, for 10 minutes)
Number of subjects: 16
Study 15296367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (3 MHz, 1.0 W/cm2, 50% duty cycle, for 10 minutes)
Number of subjects: 16
Study 11055474 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil/hydrochlorothiazide (candesartan/HCT; 16/12.5 mg)
Number of subjects: 299
Study 11055474 — intervention group
Group type: COMPARATOR
Intervention: Losartan/hydrochlorothiazide (losartan/HCT; 50/12.5 mg)
Number of subjects: 299
Study 8379551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program (10 weeks of group therapy)
Number of subjects: 33
Study 8379551 — intervention group
Group type: COMPARATOR
Intervention: Slow taper condition alone
Number of subjects: 33
Study 2875594 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 0
Study 2875594 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg
Number of subjects: 0
Study 2875594 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 0
Study 2875594 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 0
Study 2875594 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0.1 mg
Number of subjects: 0
Study 2875594 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0.1 mg-droperidol 5 mg
Number of subjects: 0
Study 2875594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31581295 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% estimated caloric needs (ECN)
Number of subjects: 35
Study 31581295 — intervention group
Group type: COMPARATOR
Intervention: 40% estimated caloric needs (ECN)
Number of subjects: 35
Study 29665102 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of broad-spectrum antibiotics followed by FMT from a donor enriched in Lachnospiraceae and Ruminococcaceae
Number of subjects: 0
Study 29665102 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC, no antibiotics/FMT)
Number of subjects: 0
Study 26763986 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPEMB (vinblastine, cyclophosphamide, procarbazine, prednisone, etoposide, mitoxantrone, bleomycin)
Number of subjects: 54
Study 26763986 — intervention group
Group type: COMPARATOR
Intervention: ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 54
Study 26763986 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPEMB
Number of subjects: 54
Study 26763986 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 54
Study 24446022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 245
Study 24446022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation with early reablation
Number of subjects: 245
Study 22200586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer group
Number of subjects: 655
Study 22200586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer group (among participants who completed the intervention)
Number of subjects: 655
Study 22200586 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 655
Study 21052040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 617
Study 21052040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study 18274940 — intervention group
Group type: COMPARATOR
Intervention: Active recovery
Number of subjects: 10
Study 18274940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (10 degrees C, 15 degrees C, 20 degrees C)
Number of subjects: 10
Study 18274940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 10
Study 16181465 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% 5-fluorouracil (5-FU) cream applied twice daily for 3 weeks
Number of subjects: 20
Study 16181465 — intervention group
Group type: COMPARATOR
Intervention: 5% 5-fluorouracil (5-FU) cream applied twice daily for 1 day per week for 12 weeks
Number of subjects: 20
Study 16181465 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of inflammation scores
Number of subjects: 20
Study 12680810 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 2 (T2) - Communicative Reading Strategies (CRS)
Number of subjects: 12
Study 12680810 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 1 (T1) - Traditional decoding‐based feedback strategies
Number of subjects: 12
Study 12680810 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 12
Study 10686664 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (3 x 1 g daily for 120 days)
Number of subjects: 41
Study 10686664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8836270 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (15-20 mg/kg.h) with 30% O2 in air
Number of subjects: 90
Study 8836270 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (10-15 mg/kg.h) with 30% O2 in N2O
Number of subjects: 90
Study 8836270 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (1.0-1.5 Vol%) with 30% O2 in N2O
Number of subjects: 90
Study 1364936 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated naproxen tablets (ECT)
Number of subjects: 98
Study 1364936 — intervention group
Group type: COMPARATOR
Intervention: Plain naproxen tablets (PT)
Number of subjects: 98
Study 1364936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ECT and PT
Number of subjects: 98
Study 4055463 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills-building methods
Number of subjects: 331
Study 4055463 — intervention group
Group type: COMPARATOR
Intervention: Discussion methods
Number of subjects: 331
Study 4055463 — intervention group
Group type: COMPARATOR
Intervention: Pretest-posttest
Number of subjects: 331
Study 4055463 — intervention group
Group type: COMPARATOR
Intervention: Posttest only
Number of subjects: 331
Study 31140540 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 108
Study 31140540 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 108
Study 29455404 — intervention group
Group type: EXPERIMENTAL
Intervention: Online lecture (15-min duration, watched 1-2 weeks prior to surgery)
Number of subjects: 200
Study 29455404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no online lecture)
Number of subjects: 200
Study 29455404 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 200
Study 26935407 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS-RDAVR via upper hemisternotomy (EDWARDS INTUITY)
Number of subjects: 100
Study 26935407 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS-RDAVR
Number of subjects: 100
Study 26935407 — intervention group
Group type: COMPARATOR
Intervention: FS-AVR
Number of subjects: 100
Study 24107324 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg/day
Number of subjects: 2340
Study 24107324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2340
Study 22954919 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-frequency low-dose intravenous iron (iron sucrose 25 mg, twice a week for 8 weeks)
Number of subjects: 58
Study 22954919 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-frequency regular-dose intravenous iron (iron sucrose 100 mg, once every two weeks for 8 weeks)
Number of subjects: 58
Study 22954919 — intervention group
Group type: COMPARATOR
Intervention: Non-iron group
Number of subjects: 58
Study 20488261 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (15mg RE)
Number of subjects: 888